BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22248270)

  • 1. Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma.
    Wang Z; Zheng T; Wu Q; Wang J; Wu C; Wang J
    Neoplasma; 2012; 59(2):137-41. PubMed ID: 22248270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer.
    Alabdullah ML; Ahmad DA; Moseley P; Madhusudan S; Chan S; Rakha E
    J Obstet Gynaecol; 2019 May; 39(4):522-528. PubMed ID: 30712414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas.
    Lee D; Do IG; Choi K; Sung CO; Jang KT; Choi D; Heo JS; Choi SH; Kim J; Park JY; Cha HJ; Joh JW; Choi KY; Kim DS
    Mod Pathol; 2012 Jan; 25(1):131-9. PubMed ID: 21874010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer.
    No JH; Jeon YT; Park IA; Kim YB; Kim JW; Park NH; Kang SB; Han JY; Lim JM; Song YS
    Gynecol Oncol; 2011 Apr; 121(1):8-12. PubMed ID: 21276607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of Akt/mTOR pathway is associated with poor prognosis of nasopharyngeal carcinoma.
    Wang W; Wen Q; Xu L; Xie G; Li J; Luo J; Chu S; Shi L; Huang D; Li J; Fan S
    PLoS One; 2014; 9(8):e106098. PubMed ID: 25165983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.
    Chen S; Nakahara T; Uchi H; Takeuchi S; Takahara M; Kido M; Dugu L; Tu Y; Moroi Y; Furue M
    Br J Dermatol; 2009 Aug; 161(2):357-63. PubMed ID: 19438435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis.
    Okumura Y; Kohashi K; Tanaka Y; Kato M; Maehara Y; Ogawa Y; Oda Y
    Virchows Arch; 2020 Jun; 476(6):881-890. PubMed ID: 31927624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma.
    Wu H; Liu Y; Jiang XW; Li WF; Guo G; Gong JP; Ding X
    Tumour Biol; 2016 Oct; 37(10):13499-13508. PubMed ID: 27465555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of phosphorylated mTOR and its regulatory protein is related to biological behaviors of ameloblastoma.
    Li N; Zhong M; Song M
    Int J Clin Exp Pathol; 2012; 5(7):660-7. PubMed ID: 22977662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides.
    Levidou G; Siakantaris M; Papadaki T; Papadavid E; Vassilakopoulos TP; Angelopoulou MK; Marinos L; Nikolaou V; Economidi A; Antoniou C; Patsouris E; Korkolopoulou P
    J Am Acad Dermatol; 2013 Sep; 69(3):375-84. PubMed ID: 23685026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.
    Korkolopoulou P; Levidou G; El-Habr EA; Piperi C; Adamopoulos C; Samaras V; Boviatsis E; Thymara I; Trigka EA; Sakellariou S; Kavantzas N; Patsouris E; Saetta AA
    Histopathology; 2012 Aug; 61(2):293-305. PubMed ID: 22690797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
    Castellvi J; Garcia A; Rojo F; Ruiz-Marcellan C; Gil A; Baselga J; Ramon y Cajal S
    Cancer; 2006 Oct; 107(8):1801-11. PubMed ID: 16983702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours.
    Kasajima A; Pavel M; Darb-Esfahani S; Noske A; Stenzinger A; Sasano H; Dietel M; Denkert C; Röcken C; Wiedenmann B; Weichert W
    Endocr Relat Cancer; 2011 Feb; 18(1):181-92. PubMed ID: 21159731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy.
    Beelen K; Hoefnagel LD; Opdam M; Wesseling J; Sanders J; Vincent AD; van Diest PJ; Linn SC
    Int J Cancer; 2014 Sep; 135(5):1257-63. PubMed ID: 24501006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical analysis of phosphorylated mammalian target of rapamycin and its downstream signaling components in invasive breast cancer.
    Ma BL; Shan MH; Sun G; Ren GH; Dong C; Yao X; Zhou M
    Mol Med Rep; 2015 Oct; 12(4):5246-54. PubMed ID: 26151180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High levels of phosphatase and tensin homolog expression are associated with tumor progression, tumor recurrence, and systemic metastases in pT1 urothelial carcinoma of the bladder: a tissue microarray study of 156 patients treated by transurethral resection.
    Chaux A; Compérat E; Varinot J; Hicks J; Lecksell K; Solus J; Netto GJ
    Urology; 2013 Jan; 81(1):116-22. PubMed ID: 23273076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of phosphorylated 4E-binding protein 1 predicts lymph node metastasis and poor prognosis of Chinese patients with hilar cholangiocarcinoma.
    Fang Z; Lu L; Tian Z; Luo K
    Med Oncol; 2014 May; 31(5):940. PubMed ID: 24706262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of key mTOR pathway components in pancreatic ductal adenocarcinoma: A multicenter study for clinicopathologic and prognostic significance.
    Zhou L; Yuan D; Zhang ZG; Liang ZY; Zhou WX; Yang JY; Jiang SH; Lu J; Zhang TP; You L; Guo JC; Zhao YP
    Cancer Lett; 2017 Jun; 395():45-52. PubMed ID: 28279716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.
    Yamada Y; Kohashi K; Fushimi F; Takahashi Y; Setsu N; Endo M; Yamamoto H; Tokunaga S; Iwamoto Y; Oda Y
    Cancer; 2014 Mar; 120(6):864-76. PubMed ID: 24353015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma.
    Tasioudi KE; Sakellariou S; Levidou G; Theodorou D; Michalopoulos NV; Patsouris E; Korkolopoulou P; Saetta AA
    APMIS; 2015 Aug; 123(8):639-47. PubMed ID: 25912437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.